Naloxone

# Research Output: Naloxone (PSX-0274)

---

## Chemical Identity

**Verified via PubChem CID 5284596 and cross-referenced with the brief's seed data.**

| Field | Value | Source |
|---|---|---|
| PubChem CID | 5284596 | PubChem (api_verified) |
| IUPAC Name | (4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one | PubChem |
| Molecular Formula | C₁₉H₂₁NO₄ | PubChem (confirmed, matches brief) |
| Molecular Weight | 327.4 g/mol | PubChem (confirmed, matches brief) |
| InChIKey | UZHSEJADLWPNLE-GRGSLBFTSA-N | PubChem |
| SMILES (free base) | OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O | WebSearch/PubChem |
| CAS (free base) | 465-65-6 | WebSearch |
| CAS (HCl salt) | 357-08-4 | WebSearch |
| Melting point | 184°C | WebSearch (ChemicalBook) |
| Water solubility (HCl salt) | 73 mg/mL | WebSearch |
| Solubility (ethanol) | 3.3 mg/mL | WebSearch |
| Solubility (methanol) | 50 mg/mL | WebSearch |
| Insoluble in | Diethyl ether | WebSearch |

**Seed data discrepancies:** The brief lists SMILES and PubChem CID as blank — both are now confirmed above and should be populated. The molecular formula and molecular weight match the brief. The IUPAC name matches. The InChIKey is absent from the brief and should be added.

**Chemical class note:** Naloxone is an N-allyl derivative of oxymorphone (a morphinan alkaloid). The N-methyl group present in oxymorphone is replaced by an N-allyl (prop-2-en-1-yl) group — the same structural modification that converts most opioid agonists into antagonists (nalorphine from morphine, naltrexone from oxymorphone with an additional ring modification). The 4,5-epoxy morphinan scaffold and 6-oxo ketone group are key structural features.

---

## Pharmacology

### Mechanism of Action

Naloxone is a **competitive antagonist** at opioid receptors, primarily the mu-opioid receptor (MOR), with lower affinity for kappa (KOR) and delta (DOR) subtypes [Ref 1]. It works by competitive displacement of opioid agonists from receptor binding sites. The degree of displacement depends on the relative affinity of the agonist vs. naloxone and the relative concentrations of each [Ref 1].

A 2025 cryo-EM study (Nature) capturing 8 structural models and 16 maps of MOR in complex with naloxone revealed that naloxone stalls MOR in a "latent" state that differs from the fully inactive or activated conformations, distinct from loperamide (which promotes an "engaged" pre-activation state). This structural insight explains naloxone's efficacy as an antagonist and potentially mild inverse agonist properties at some receptor conformations [Ref 9].

Some literature describes naloxone as having inverse agonist properties at high concentrations (increasing GDP affinity, dampening baseline MOR signaling), while acting as a competitive antagonist at clinically relevant concentrations [Ref 9].

### Receptor Binding Affinities

From IUPHAR/BPS Guide to PHARMACOLOGY (ligandId=1638) [Ref 23]:

| Receptor | Species | pKi | Ki (nM, approx.) | Activity |
|---|---|---|---|---|
| Mu-opioid (MOR) | Human | 8.9 | ~1.26 nM | Antagonist |
| Mu-opioid (MOR) | Mouse | 9.0 | ~1.0 nM | Antagonist |
| Kappa-opioid (KOR) | Human | 7.6–8.6 | ~2.5–25 nM | Antagonist |
| Kappa-opioid (KOR) | Rat | 7.7–8.0 | ~10–16 nM | Antagonist |
| Delta-opioid (DOR) | Human | 7.2 | ~63 nM | Antagonist |
| Delta-opioid (DOR) | Mouse | 7.8 | ~16 nM | Antagonist |

**Selectivity profile:** Naloxone is most potent at MOR (~50-fold selectivity over DOR in humans), with intermediate KOR affinity. This is consistent with the database classification of naloxone as primarily a mu- and kappa-opioid receptor antagonist. The NOP/ORL1 receptor (nociceptin receptor) has negligible naloxone affinity — confirming that naloxone does not reverse nociceptin-mediated effects.

**Naloxone vs. carfentanil/nitazenes context:** Naloxone's competitive mechanism becomes increasingly challenged by opioids with high receptor affinity and slow dissociation kinetics. Carfentanil stabilizes MOR conformations resistant to naloxone and nalmefene displacement (Endt et al. 2025 [Ref not separately cited]). Nitazenes (protonitazene, ethonitazene) have longer MOR dissociation half-lives than fentanyl, requiring fourfold higher antagonist concentrations for displacement [Ref 11]. This context is critical for current clinical practice [Ref 27, 28].

### Pharmacokinetics

**Primary reference:** Saari, Strang & Dale (2024), *Clinical Pharmacokinetics*, a comprehensive PK/PD review [Ref 1].

#### Routes of Administration

**Intravenous (IV):**
- Bioavailability: 100%
- Onset: 1–2 minutes
- Duration of action: ~2 hours for 1 mg IV [Ref 1]
- Half-life: 60–120 min (varies considerably between/within subjects) [Ref 1]

**Intramuscular (IM):**
- Relative bioavailability: 36–41% [Ref 5, 6]
- Tmax: ~12 minutes median [Ref 6]
- Duration: Possibly longer than IV due to depot effect [Ref 1]
- At 5 mg IM: Cmax ~337% of 2 mg IM dose; AUC ~277% [Ref 29]

**Intranasal (IN):**
- Bioavailability varies sharply by formulation:
  - Early dilute formulations (0.4 mg/mL): ~4% bioavailability [Ref 6]
  - Concentrated modern formulations (e.g., 8 mg/mL): ~40–55% relative bioavailability [Ref 3, 5]
  - Narcan 4 mg nasal spray: ~50% [Ref 1]
  - RiVive 3 mg nasal spray: comparable to Narcan [Ref 20]
- Tmax: 15–30 min (mean) [Ref 1]; nasal uptake is generally slower than IM in clinical conditions
- Note: Opioid agonists may increase bioavailability of nasally administered naloxone [Ref 8]
- Respiratory reversal may lag behind IM naloxone due to slower absorption [Ref 1]

**Oral:**
- Very low bioavailability due to extensive first-pass hepatic metabolism
- Not used clinically for acute overdose reversal
- Oral doses in the 4–28 mg range produce minimal systemic exposure; used in bowel dysfunction (peripheral mu-antagonist applications)
- **Flag:** The seed data dose ranges for oral route (Threshold 4 mg, Light 4–8 mg, Common 8–16 mg, Strong 16–28 mg, Heavy 28+ mg) may reflect unconventional or off-label use contexts rather than standard clinical practice. These require editorial review as to what subjective experience context is intended.

#### Distribution and Elimination

- Volume of distribution: Large (estimated 2–2.5 L/kg based on population PK) [Ref 6]
- Protein binding: ~45%
- Clearance: ~91 L/hr (population PK in healthy volunteers) [Ref 6]
- Half-life: 60–120 min; one review cites elimination t½ ~33 min [Ref 10] — the shorter value likely reflects a faster beta phase or different measurement method; the 60–120 min range is more widely cited

#### Metabolism

Naloxone is primarily metabolized via **UDP-glucuronosyltransferase (UGT)-mediated glucuronidation**, not cytochrome P450 (CYP) enzymes [Ref 18]. The principal metabolite is naloxone-3-glucuronide. Additional minor metabolites include naloxone-N-oxide. All known metabolites are **inactive** [Ref 1]. Extrahepatically, UGT enzymes in kidney and intestine also contribute to clearance [Ref 18]. PBPK modeling of naloxone confirms hepatic glucuronidation as the primary clearance pathway with systemic clearance predictions within 1.5-fold of observed values [Ref 18].

---

## History

### Discovery and Synthesis

Naloxone was first synthesized in **1960** by chemist Jack Fishman working in the laboratory of **Mozes J. Lewenstein** at Endo Laboratories (a subsidiary of DuPont) [Ref 17, 31]. The synthesis arose from an effort to create a "pure" opioid antagonist — one without the partial agonist properties of earlier compounds like nalorphine. **Harold Blumberg** at Endo Laboratories proposed the key structural modification: replacing the N-methyl group of oxymorphone with an N-allyl (prop-2-en-1-yl) group, generating naloxone [Ref 17]. Blumberg and colleagues subsequently established that naloxone was approximately 10–20 times more potent as a narcotic antagonist in animals than nalorphine [Ref 17].

The compound was **patented in 1961** by Lewenstein, Fishman, and the Japanese pharmaceutical company Sankyo [Ref 17].

The broader intellectual history preceding this synthesis — spanning 1915–1960 — involved a half-century of failed attempts to find a "pure" antagonist before naloxone's discovery, reflecting deep cultural and pharmacological ambivalence about opioids as both agents of relief and risk (Kolbe & Fins 2021 [Ref 17]).

### Regulatory History

- **1971:** FDA approved naloxone injection (IV/IM/SC routes) under the brand name Narcan [Ref 21]
- **2014:** FDA approved Evzio, a 0.4 mg prefilled auto-injector for IM/SC use [Ref 21]
- **2015:** FDA approved Narcan 4 mg prefilled nasal spray [Ref 21]
- **March 29, 2023:** FDA approved Narcan 4 mg nasal spray for **over-the-counter (OTC)** use without prescription — the first OTC naloxone product in the US [Ref 20]
- **July 2023:** FDA approved RiVive 3 mg nasal spray OTC [Ref 20]
- Naloxone has been on the WHO List of Essential Medicines and is described as a well-established essential medicine [Ref 19]

### Take-Home Naloxone Programs

Over two decades beginning in the early 2000s, the concept of "take-home naloxone" (THN) evolved: pre-provision of emergency naloxone supplies to laypersons likely to witness opioid overdoses (peers, family members, first responders) [Ref 19]. Scotland's National Naloxone Programme (NNP), launched January 2011, was associated with a 36% reduction in the proportion of opioid-related deaths occurring within 4 weeks of prison release, representing an estimated 42 fewer deaths during 2011–2013 when ~12,000 kits were issued [Ref 16].

---

## Subjective Effects

**Critical framing note:** Naloxone is not a psychoactive substance in the conventional sense. Its effects are entirely contingent on the opioid status of the recipient:

### In Opioid-Naive Individuals
At standard clinical doses (0.4–4 mg), naloxone produces **minimal direct subjective effects** in opioid-naive persons. Endogenous opioid blockade may produce mild increases in pain sensitivity (hyperalgesia) and slight reductions in stress-induced analgesia, but these are subtle and rarely clinically meaningful at standard doses. No meaningful euphoria, sedation, or perceptual effects have been documented in opioid-naive subjects at therapeutic doses.

### In Opioid-Dependent Individuals: Precipitated Withdrawal
Naloxone's signature subjective effect in opioid-dependent people is **precipitated withdrawal** — a rapid, abrupt opioid withdrawal syndrome (Martinez et al. 2026 [Ref 15]) characterized by:

**Somatic:** Anxiety, agitation, restlessness, nausea, vomiting, diarrhea, diaphoresis, lacrimation, yawning, rhinorrhea, piloerection (gooseflesh), myalgia, tremor, tachycardia, hypertension
**Affective:** Dysphoria, irritability, craving
**Timing:** Onset within 2–5 minutes of IV/IM administration; may be delayed 15–30 minutes with IN formulations
**Duration:** Parallels naloxone's duration of action (~1–2 hours); may recur if renarcotization occurs

Precipitated withdrawal is more severe and abrupt than spontaneous withdrawal, causing significant distress. It is a deliberate contraindication concern in clinical management: **the goal of overdose reversal is to restore respiration, NOT to precipitate full consciousness or withdrawal** (Saari et al. 2024 [Ref 1]).

### Renarcotization Risk
Because naloxone's half-life (60–120 min) is shorter than many opioids it reverses (morphine ~2–3 h; fentanyl significantly redistributes), opioid overdose symptoms can re-emerge ("renarcotization") after naloxone wears off [Ref 28]. This is particularly relevant for fentanyl, long-acting opioids (methadone), and extended-release formulations.

### Effect Profile Assessment of Seed Data
The five seed effects (dehydration-sensation, nausea, sedation, emotional-suppression, identity-alteration) all have null intensity/frequency values and community_consensus_large/medium provenance. Assessment:

- **Nausea:** Documented — occurs as part of precipitated withdrawal in opioid-dependent individuals. Not a direct effect in opioid-naive persons at standard doses. Confirmed. Should be marked as occurring specifically in opioid-dependent context.
- **Sedation:** **Flagged** — naloxone does NOT cause sedation; it reverses sedation caused by opioids. Sedation would be the opposite of its effect profile. This entry appears to be an error or mislabeled (possibly describing residual sedation from the opioid being reversed). Requires editorial review.
- **Dehydration-sensation:** Plausible as part of precipitated withdrawal (diaphoresis, vomiting). Not a primary direct effect.
- **Emotional-suppression:** Ambiguous — in opioid-naive individuals, blocking endogenous opioid tone could theoretically reduce emotional reward/pleasure; some research suggests naloxone attenuates placebo effects. However, "emotional-suppression" as a community-reported experience is unverified in published literature for naloxone specifically.
- **Identity-alteration:** No published evidence supports identity-alteration as a naloxone effect in any context. This appears unlikely and should be flagged for removal or justification.

---

## Safety & Toxicity

### Direct Toxicity of Naloxone
**Naloxone itself has very low direct toxicity.** It does not cause respiratory depression, sedation, or classical opioid toxicity at any clinically relevant dose. Published LD50 data in animals is high (specific values not retrieved in this research; the compound is not considered acutely toxic to opioid-naive subjects).

**⚠️ FLAG — Seed data toxicity label:** The brief states "Acute: high; Chronic: high" with the note "Inferred from pharmacological class — not sourced from literature. Review recommended." This is **incorrect** for naloxone specifically. Naloxone belongs to the opioid pharmacological class, but its toxicity profile is the inverse of opioid agonists — it reverses toxicity rather than causing it. The "high" acute toxicity label should be corrected. The actual acute toxicity risk from naloxone administration is:
- **Low** in opioid-naive individuals (minimal pharmacodynamic effect)
- **High risk of precipitated withdrawal** in opioid-dependent individuals (not toxicity per se — a pharmacological effect)

### Adverse Events Documented in Literature

**Cardiovascular:** Hypertension, tachycardia, cardiac arrhythmias (associated with catecholamine surge from rapid withdrawal precipitation or reversal of opioid-induced hemodynamic effects)

**Pulmonary:** Noncardiogenic pulmonary edema — rare but documented. Proposed mechanism: catecholamine surge secondary to abrupt opioid reversal causes volume shift to pulmonary vasculature (Elkattawy et al. 2021 [Ref 24]). Appears more common with higher doses. Generally manageable with diuretics and oxygen supplementation.

**Neurological:** Seizures (rare); agitation

**Gastrointestinal:** Nausea, vomiting (primarily as withdrawal symptoms in opioid-dependent individuals)

**Xylazine context:** Naloxone does not reverse xylazine (a veterinary tranquilizer increasingly found as a fentanyl adulterant). When xylazine is present, naloxone will reverse the opioid component of respiratory depression, but the alpha-2 agonist effects of xylazine will persist, necessitating hospitalization [Ref 28].

### Contraindications
- Hypersensitivity to naloxone or any formulation components
- Use with caution in: known or suspected opioid dependence (precipitated withdrawal risk); cardiovascular disease (catecholamine-mediated hemodynamic effects); patients receiving medications that could interact with withdrawal-related sympathetic stimulation

### High-Dose Safety Context
The current fentanyl overdose era has prompted clinical questions about high-dose naloxone. From Dahan et al. (2024) [Ref 28]: higher naloxone doses (5 mg IM, 8 mg IN) are important additions for synthetic opioid overdose treatment. Concerns about severe withdrawal symptoms and pulmonary edema exist, but for first responders managing life-threatening overdoses, the risk-benefit calculation favors adequate dosing.

---

## Harm Reduction

### Core Principle
The goal of naloxone administration in opioid overdose is **restoration of respiration, NOT restoration of consciousness or precipitation of withdrawal**. Saari et al. (2024) [Ref 1] describe this as "a balancing act between restoration of respiration (not consciousness) and avoidance of withdrawal, achieved by titration to response."

### Dosing Strategy
- Initial doses 0.4–0.8 mg IV/IM are generally sufficient for heroin overdose [Ref 1]
- Fentanyl and synthetic opioid overdoses likely require higher doses [Ref 1, 27, 28]
- Repeat dosing may be required due to renarcotization (naloxone wears off before opioid)
- Laypeople should always carry at least TWO dose kits [Ref 1]

### Take-Home Naloxone
- Pre-provision to likely bystanders is effective at population level (Scotland NNP: 36% reduction in prison-release OD deaths [Ref 16])
- Multiple formulations now approved: nasal sprays (4 mg Narcan, 3 mg RiVive — OTC US), auto-injectors (Evzio), prefilled syringes
- Safety margin of approved nasal sprays is superior to improvised nasal kits [Ref 19]

### Emergency Response Guidance
Per Dahan et al. (2024) [Ref 28]: calling emergency services after naloxone administration is essential even when the patient revives, because renarcotization risk from fentanyl and its analogs is substantial given naloxone's short half-life.

### Testing and Identification
Naloxone itself cannot be easily identified by standard drug test strips. Fentanyl test strips are available for harm reduction. Naloxone formulations are identified by packaging; the presence of Narcan 4 mg (blue packaging), RiVive 3 mg (red packaging), or Evzio auto-injector should be stored visibly accessible.

---

## Tolerance & Dependence

### Tolerance
Naloxone itself does **not** produce the classical receptor tolerance associated with opioid agonists. It is an antagonist — it does not activate downstream signaling cascades that lead to receptor desensitization in the traditional opioid tolerance sense. No published human literature documents meaningful dose escalation requirements for naloxone due to tolerance.

### Dependence
Naloxone is **not habit-forming** and does not produce physical or psychological dependence under clinical use conditions. This aligns with the seed data designation ("Formation: not habit-forming"). There is no documented withdrawal syndrome from naloxone cessation.

### Relevant Context: Suboxone
Naloxone is combined with buprenorphine in Suboxone (buprenorphine/naloxone sublingual film) specifically because naloxone is poorly absorbed sublingually but active if injected — serving as a deterrent to injection misuse of buprenorphine formulations. The naloxone component in Suboxone does not contribute meaningfully to the therapeutic or dependence pharmacology when taken as prescribed [Ref 19].

---

## Interactions

### Heroin and Opioid Agonists (Primary Interaction)
The primary pharmacological interaction of naloxone is **competitive displacement of opioid agonists** from mu-, kappa-, and delta-opioid receptors. This interaction is the basis of its clinical use. The seed data lists heroin: low_risk, which is accurate — naloxone is the treatment for heroin overdose, and the interaction is well-characterized and manageable when administered correctly [Ref 1].

**Interaction severity by opioid type:**
- **Heroin/morphine:** Standard doses (0.4–0.8 mg IV/IM) generally sufficient [Ref 1]
- **Fentanyl and analogs:** Higher doses likely required; concern about rapid OD onset leaving insufficient time window for reversal [Ref 1, 27, 28]
- **Carfentanil:** MOR conformations stabilized by carfentanil show resistance to naloxone and nalmefene displacement [Ref 10]
- **Methadone:** Long-acting opioid; multiple naloxone doses or infusion may be required; buprenorphine has been compared as alternative [Ref 14]
- **Buprenorphine:** High MOR affinity means buprenorphine is difficult to displace; however, at high naloxone doses, partial reversal is possible

### Remifentanil PK Interaction
Opioid agonists (demonstrated with remifentanil) may increase the bioavailability of nasally administered naloxone — a pharmacokinetic interaction of clinical relevance for the IN route [Ref 8].

### Non-Opioid Interactions
- No significant CYP-mediated drug interactions expected (naloxone is UGT-cleared, not CYP-dependent [Ref 18])
- Potential pharmacodynamic interactions with alpha-2 agonists (xylazine, clonidine) — naloxone does not reverse non-opioid CNS effects [Ref 28]

---

## Legal Status

### United States
- Naloxone injectable formulations: No controlled substance scheduling (not a DEA scheduled substance)
- **Narcan 4 mg nasal spray:** OTC without prescription since March 29, 2023 (FDA approval [Ref 20])
- **RiVive 3 mg nasal spray:** OTC since July 2023
- Other formulations (higher-dose, generic injection): Prescription required in some states; many states have standing orders or pharmacist dispensing authority
- Some states mandate co-prescription with opioid prescriptions [Ref 22]

### United Kingdom
- Naloxone is a Prescription Only Medicine (POM)
- Since 2005: Legally may be administered by any member of public as a life-saving measure (even without prescription)
- Since 2015: National legislation allows drug service staff to supply naloxone without prescription under Patient Group Directions/standing orders
- Take-home naloxone programs operate under these provisions [Ref 19, 32]

### Canada
- Not a controlled substance
- Pharmacy-level dispensing without prescription available in several provinces (varies by province)
- Provincial programs provide free naloxone kits in many settings [Ref 20]

### Australia
- Available without prescription in pharmacies
- Government-subsidized through various harm reduction programs [Ref 20]

### European Union / Europe
- Most EU countries require medical prescription
- Italy: OTC classification since 1996 [Ref 32]
- France: Some formulations available without prescription [Ref 32]
- EUDA recommends expanding access across EU member states [Ref 32]

---

## Clinical Trials

From ClinicalTrials.gov search:

| NCT ID | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT03518021 | Naloxone Nasal Spray Compared With Naloxone Injection for Opioid Overdoses Outside the Hospital | COMPLETED | Phase 3 | Norwegian University of Science and Technology |
| NCT05338632 | Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists | RECRUITING | Phase 1 | Leiden University Medical Center |
| NCT02307721 | Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use | COMPLETED | Phase 1 | Norwegian University of Science and Technology |
| NCT05114460 | Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal | TERMINATED | Phase 2 | New York State Psychiatric Institute |
| NCT05072249 | European Cohort Study of the Effectiveness of Take Home Naloxone (NalPORS) | UNKNOWN | Observational | King's College London |

**Published equivalence data:** NCT02307721 produced a 2019 publication (Skulberg et al. [Ref 2]) showing that 1.4 mg IN naloxone achieves systemic exposure comparable to 0.8 mg IM naloxone.

**Meta-analysis:** Fischer et al. (2025) [Ref 25] conducted a systematic review and meta-analysis of naloxone distribution in community settings (OEND programs) showing significant reductions in opioid overdose deaths in community settings.

---

## Community Feedback Analysis

No community feedback was submitted for this substance (Part A2 of the brief was empty).

---

## Gaps & Flags

### 🚩 SAFETY-CRITICAL FLAGS

1. **Toxicity data inaccurate (seed data):** The brief states "Acute: high; Chronic: high" for toxicity, with an explanatory note that this is "inferred from pharmacological class." This is **incorrect** for naloxone. Naloxone has very low direct toxicity — it does not cause respiratory depression, sedation, or organ toxicity at clinical doses in opioid-naive individuals. The risk in opioid-dependent individuals is precipitated withdrawal (a pharmacological effect, not toxicity per se). **Editorial action required: Correct toxicity classification to reflect actual naloxone safety profile.**

2. **Sedation in effect profile:** The seed effect "sedation" is listed as a community-consensus effect. Published literature does not support sedation as a direct naloxone effect; naloxone *reverses* sedation. This entry is likely an error in the community data curation. **Editorial action required: Remove or reframe sedation entry.**

3. **Identity-alteration in effect profile:** No published evidence supports identity-alteration as a naloxone effect. **Editorial action required: Investigate provenance or remove.**

### ⚠️ DATA QUALITY FLAGS

4. **"Emerging" characterization incorrect:** The brief characterizes naloxone as "emerging." Naloxone has been in clinical use since 1971 (FDA approved) and has been an WHO Essential Medicine for decades. It is one of the most widely deployed pharmacological agents in emergency medicine globally. This should be updated to "established" or "approved."

5. **Primary ROA listed as "insufflated":** Clinically, IV and IM are the primary routes in hospital/prehospital settings; insufflated (intranasal) is the primary community/lay-person route. The designation may be contextually appropriate for the Psychedex harm-reduction framing but should be noted.

6. **SMILES and PubChem CID missing from seed:** Both are now confirmed (CID: 5284596; SMILES: OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O) and should be populated in the database.

7. **Oral dose data context unclear:** The seed oral doses (Threshold 4 mg through Heavy 28+ mg) do not correspond to standard clinical practice (oral naloxone is not used for OD reversal due to near-complete first-pass metabolism). These may relate to oral MOUD formulations, peripheral opioid antagonist uses (constipation), or low-dose naloxone (LDN) off-label use. Context and source require editorial review.

8. **IM onset discrepancy:** The seed lists IM onset as 0.25–2 minutes. Published literature (Dowling et al. 2008 [Ref 6]) documents median Tmax of 12 minutes for IM. Onset of reversal and Tmax are different metrics, but 0.25–2 min onset for IM seems too fast. **Flag for editorial verification.**

9. **Effect profile requires major rework:** All five seed effects require editorial attention. The effect taxonomy proposed appears to conflate opioid withdrawal symptoms (caused by naloxone in opioid-dependent individuals) with direct pharmacological effects of naloxone itself. A cleaner framing would distinguish:
   - Effects in opioid-naive individuals (minimal/none at clinical doses)
   - Withdrawal precipitating effects in opioid-dependent individuals (nausea, restlessness, pain-enhancement, anxiety, dysphoria, trembling, vomiting, diarrhea, yawning, watery-eyes, excessive-sweating, tachycardia)

10. **Controlled clinical trial data absent for synthetic opioids:** Saari et al. (2024) [Ref 1] explicitly note that "controlled clinical trials are feasible in opioid overdose but are absent in cohorts with synthetic opioids." This is a significant gap for dosing guidance in the current fentanyl era.

11. **LD50 data not retrieved:** Specific LD50 values for naloxone in animals were not found in this literature search. The PDSP/ChEMBL databases or FDA drug label may contain this information. Not safety-critical for overdose reversal agents where the compound itself is non-toxic.

12. **Binding affinity values:** The Ki values reported are from the IUPHAR/BPS database (web_retrieved, not api_verified from a primary research paper). For the generation agent: these values are widely accepted reference values compiled from multiple primary studies and are considered authoritative. The cited pKi values are consistent with what is expected for naloxone based on published pharmacology.